PubMed Health⌕ Search

Biomedical subjects

E Saxén

Publications and source records attributed to E Saxén.

12 recordsLinked to original sources
PubMed1985

Breast tumors with a solid and uniform carcinoid pattern. Ultrastructural and immunohistochemical study of two cases.

Two cases of breast tumors with a uniform solid carcinoid pattern and argyrophilic dense-core granules were analyzed by immunohistochemistry in order to compare their characteristics with known features of other carcinoid tumors and ordinary breast carcinomas. The tumors were positive for keratin-type intermediate filaments, neuron-specific enolase and alpha-chain of human chorion gonadotropin but negative for vimentin and S-100 protein. Laminin was found only in a rim between tumor cell islands and stroma but not among the cells. It is concluded that these tumors are histologically, ultrastructurally and immunohistochemically similar to other carcinoid tumors. The present results suggest that both breast carcinoids and carcinomas may have a common precursor in the mammary secretory unit.

Aged↗
PubMed1979

Epidemiology of colon cancer in Scandinavia.

The occurrence of colon cancer in four Scandinavian (Nordic) countries--Finland, Denmark, Norway and Sweden--is described. In addition, a number of correlations relevant to the etiology of colon cancer are presented. The observable differences in the risk for colon cancer among the Nordic countries can largely be accounted for by socioeconomic factors.

Adult↗
PubMed1978

Observer variation in histologic classification of thyroid cancer.

Histologic slides of 696 cases of thyroid cancer reported to the national cancer registries of Finland, Iceland, Norway and Sweden were reviewed by 5 Nordic pathologists in order to determine the observer variation between the pathologists, as well as the reproducibility of the WHO classification of thyroid tumours. In 58% of the cases all observers agreed upon the diagnosis and in 82% at least three of them agreed. The observer disagreement was lowest for papillary carcinoma (7%) and highest for follicular carcinoma (27%). The corresponding figures for anaplastic and medullary carcinomas were 18% and 23%, respectively. The most common diverging diagnosis for cases finally interpreted as papillary carcinoma was follicular carcinoma, and for cases finally interpreted as follicular carcinoma, a benign thyroid lesion. The results of the present study clearly indicate the necessity of having all cases reviewed by the same pathologist or group of pathologists in order to obtain reliable results for comparative studies.

Adenocarcinoma↗
PubMed1978

Cancer of the eye, a review of trends and differentials.

An analysis was made of the incidence and mortality of cancer of the eye in different countries. In general, cancer of the eye was more common in males than in females. The differences in both incidence and mortality rates between countries were great, the white populations in Scandinavia exhibiting the highest rates. The rates were rather constant over time, and only a few increasing or decreasing trends were observable. Tumours in children 0-14 years of age and those in adults were also epidemiologically distinct entities, which suggests differences in etiology. Both incidence and mortality rates in adults were positively correlated to the latitude of the country or area, and a positive correlation was also found between the incidence or mortality rate for cancer of the eye in adults and those for cutaneous melanoma.

Age Factors↗
PubMed1976

Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland.

Two nationwide registers, the Finnish Cancer Registry and a register of persons entitled to free drugs for hypertension, were linked in a case-control study of the association of breast cancer and use of rauwolfia. Cases were all hypertensive patients in whom breast cancer was diagnosed in 1973. To test the association specifically with rauwolfia, controls were hypertensive women matched with the cases for age and geographic area and approximately matched for duration of treatment for hypertension. There were 109 case-control pairs. Use of any physician-prescribed drugs during the year prior to diagnosis of breast cancer was ascertained from original prescriptions. In the first set of analyses the patients were classified according to the drug used during most days of the year ("main antihypertensive agent"). In the second set a person qualified as a user of the respective drug regardless of the amount taken. The relative risks in the use of rauwolfia, methyldopa, another synthetic antihypertensive or a diuretic as main antihypertensive agent all ranged between 0.90 and 1.11. The results based on use of a drug in any amount were similar. Next, pairs in which duration of treatment for hypertension was different for cases and controls were excluded. The relative risk associated with use of rauwolfia as main antihypertensive agent then increased from 1.00 to 1.30 and the risk associated with use of any amount of rauwolfia from 1.16 to 2.14. Simultaneously, the relative risk in the use of digitalis was raised from 1.33 to 2.67 and of nitroglycerin from 1.00 to 1.71. Cases also used more types of antihypertensive agents simultaneously than controls. There was no association between rauwolfia-use and breast cancer in analyses limited to pairs in which neither case nor control used digitalis. Thus, there was not a consistent drug-specific association between rauwolfia-use and breast cancer in hypertensive patients. An underlying association of hypertension, heart disease or its treatment (digitalis) and breast cancer may have confounded some of the results of this and earlier studies. In conclusion, it is unlikely that use of rauwolfia increases the risk of breast cancer.

Adult↗